Suven Life Sciences to Make Oral and Poster Presentations Highlighting Clinical Development of Two Key Drug Candidates Samelisant and Masupirdine at American Academy of Neurology (AAN) 2025 Annual Meeting, San Diego, USA.

Oral presentation on Samelisant (SUVN-G3031) will provide the comprehensive positive findings from the Phase-2 study on excessive daytime sleepiness (EDS) in patients with narcolepsy and update on the next steps in clinical development of Samelisant.

Poster presentation will provide an update on the ongoing Phase-3 study of Masupirdine (SUVN-502) trial targeting agitation in patients with dementia of Alzheimer's type.

Exhibit booth # 2142 at AAN 2025 is showcasing the innovations pipeline of Suven Life Sciences.

HYDERABAD, INDIA (4-April-2025), Suven Life Sciences, a clinical-stage biopharmaceutical company focused on discovery and development of innovative therapies for Central Nervous System (CNS) disorders, is pleased to announce its participation in the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego, USA. At this prestigious event, the company will share exciting updates on its clinical pipeline, including new insights from ongoing studies and details on the next steps in clinical development. The AAN Annual Meeting is the world's largest gathering of neurologists and neuroscience professionals and offers top-tier education and the latest updates in scientific discoveries, clinical updates, and many more from around the globe.

AAN 2025 Presentation Details:

Type	Title	Session/Date/Time
Poster Presentation	Masupirdine (SUVN-502): An Update on the Phase-3 Clinical Development Program Targeting Agitation in Patients with Dementia of Alzheimer's Type	**P1: Poster Session 1** Saturday, April 5, 2025 at 11:45 AM PT
Oral Presentation	Samelisant (SUVN-G3031): Positive Results from Phase-2 Proof-of-concept, Double-blind, Placebo-controlled Study in Patients with Narcolepsy and an Update on Further Clinical Development	**S6: Sleep** Sunday, April 6, 2025 at 4:06 PM PT

Suven Life Sciences invites all attendees of AAN 2025 to join these sessions and learn more about the company's ongoing work in the field of CNS.

Team of scientists from Suven Life Sciences will engage with key opinion leaders, principal investigators, medical and regulatory advisors at AAN 2025 to discuss the global Phase-3 study design for evaluating Samelisant in the treatment of EDS in narcolepsy patients. The initiation of the global Phase-3 study is anticipated in the second half of 2025.

Suven is showcasing its innovations pipeline and comprehensive summaries at exhibit booth # 2142, AAN-2025.

About Samelisant (SUVN-G3031) Phase-2 Study: The Phase-2 clinical study was a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of Samelisant as a monotherapy in narcolepsy patients with and without cataplexy (ClinicalTrials.gov Identifier: NCT04072380). The study was conducted in USA and Canada and approximately 60 sites participated in this study. The study recruited 190 patients aged 18 to 65 years and were randomized 1:1:1 to 2 mg Samelisant, 4 mg Samelisant, or Placebo treatment groups. The primary efficacy endpoint of this study was change in ESS total score from baseline to Day 14. Secondary and exploratory endpoints were change in CGI-S score, CGI-C score and PGI-C score with regard to EDS and change in Maintenance of Wakefulness Test score from baseline to Day 14.

About Samelisant (SUVN-G3031): Samelisant is a novel, potent, selective, brain penetrant, and orally active Histamine-3 (H3) receptor inverse agonist. H3 receptor blockade elevates histamine, norepinephrine, and dopamine in the brain, a potential for the treatment of EDS and cataplexy. Samelisant exhibited wake-promoting activity in orexin knock-out mice (an animal model of narcolepsy). Pre-clinical in vitro and in vivo efficacy studies, supporting neurochemical studies, pharmacokinetic studies, safety studies and Phase-1 studies in healthy subjects under US IND have been successfully completed for Samelisant.

About Masupirdine (SUVN-502): Masupirdine is a potent and pure (highly selective) 5-HT_6 receptor antagonist with excellent pharmacokinetic properties. Masupirdine attenuated aggressive behaviors and modulated neurotransmitters having role in neuropsychiatric symptoms. In Alzheimer's patients Masupirdine significantly reduced neuropsychiatric symptoms in patients with baseline agitation/aggression. Currently, a Phase-3 study (ClinicalTrials.gov Identifier: NCT05397639) evaluating the efficacy and safety of Masupirdine in agitated Alzheimer's patients in progress.

About Suven Life Sciences ("Suven"): Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 7 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Phase-3 study ongoing); Samelisant (SUVN-G3031) for

excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Placebo-controlled Phase-2b study initiated); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study ongoing). In addition to these clinical assets, we have 8 projects in research pipeline across multiple potential indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website http://www.suven.com

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*